Tevogen Bio Holdings Inc.

DB:G28 Stock Report

Market Cap: €188.4m

Tevogen Bio Holdings Management

Management criteria checks 0/4

Tevogen Bio Holdings' CEO is Ryan Saadi, appointed in Feb 2024, has a tenure of 1.25 years. total yearly compensation is $87.76M, comprised of 0.6% salary and 99.4% bonuses, including company stock and options. directly owns 64.41% of the company’s shares, worth €121.32M. The average tenure of the management team and the board of directors is 1.3 years and 2.8 years respectively.

Key information

Ryan Saadi

Chief executive officer

US$87.8m

Total compensation

CEO salary percentage0.57%
CEO tenure1.3yrs
CEO ownership64.4%
Management average tenure1.3yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ryan Saadi's remuneration changed compared to Tevogen Bio Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$31m

Dec 31 2024US$88mUS$501k

-US$10m

Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$2m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$501kUS$501k

-US$60m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$64m

Mar 31 2023n/an/a

-US$47m

Dec 31 2022US$454kUS$453k

-US$22m

Compensation vs Market: Ryan's total compensation ($USD87.76M) is above average for companies of similar size in the German market ($USD797.52K).

Compensation vs Earnings: Ryan's compensation has increased whilst the company is unprofitable.

CEO

Ryan Saadi (59 yo)

1.3yrs
Tenure
US$87,764,783
Compensation

Dr. Ryan Saadi, M.D., M.P.H., has been Chief Executive Officer and Chairperson of Tevogen Bio Holdings Inc. since February 14, 2024. He served as Chief Executive Officer and Chairperson of Tevogen Bio begi...

Leadership Team

NamePositionTenureCompensationOwnership
Ryan Saadi
Co-Founder1.3yrsUS$87.76m64.41%
€ 121.3m
Kirti Desai
Chief Financial Officer1.3yrsUS$300.00k5.27%
€ 9.9m
Neal Flomenberg
Chief Scientific Officer and Global R&D Lead2.8yrsUS$350.00k1.76%
€ 3.3m
Stephen Chen
Chief Technical Officer3.1yrsno datano data
Mittul Mehta
Chief Information Officer & Head of Tevogen.ai1.5yrsno datano data
Tapan Shah
Head of Investor Relations & Corporate Development1.1yrsno datano data
Sadiq Khan
Chief Commercial Officer & Interim Head of Tevogen Generics1.3yrsno datano data
David Banko
Global Head of Government Affairs & Patient Accessless than a yearno datano data
1.3yrs
Average Tenure
64.5yo
Average Age

Experienced Management: G28's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Ryan Saadi
Co-Founder1.3yrsUS$87.76m64.41%
€ 121.3m
Manmohan Patel
Member of Advisory Board3.3yrsno data7.26%
€ 13.7m
Bruce Cooper
Member of Advisory Board3.3yrsno datano data
Victor Sordillo
Independent Director1.8yrsUS$478.08k0.17%
€ 313.7k
Keow Lin Goh
Independent Director2.8yrsUS$239.04k0.14%
€ 260.1k
Jeffrey Feike
Independent Director1.3yrsUS$239.04k0.32%
€ 595.9k
Susan Podlogar
Independent Director2.8yrsUS$239.04k0.11%
€ 198.6k
Curtis Patton
Independent Director1.3yrsUS$239.04k0.53%
€ 993.2k
Sten Vermund
Member of Advisory Board3.3yrsno datano data
Kendell Sprott
Member of Advisory Board2.9yrsno datano data
Afshin Beheshti
Member of Advisory Board1.3yrsno datano data
2.8yrs
Average Tenure
71yo
Average Age

Experienced Board: G28's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/21 01:03
End of Day Share Price 2025/05/21 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tevogen Bio Holdings Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.